Fundraising Fox

Spyglass Pharma

NASDAQ: SGP

Aliso Viejo, US · Founded 2019 · 77 employees on LinkedIn · 5 known investors

Find your way into Spyglass Pharma

65 people in our graph share verified history with the Spyglass Pharma team — schools, employers, funds. One of them is your warm intro.

Melissa Childersunlockedknows Malik Y. Kahook · together at University of Colorado Hospital (overlapped)
knows the team · via University of Colorado Hospital
knows the team · via Aultman Hospital
×5knows the team · via Vensana Capital
knows the team · via UPMC
knows the team · via The University of Akron

SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.

BiotechHealthtechMedical Devices

Founders & leadership

Spyglass Pharma was founded in 2019 by Glenn Sussman and Malik Y. Kahook.

GSGlenn Sussman
Glenn SussmaninCo-Founder and CTO
MYMalik Y. Kahook
Malik Y. KahookinCo-founderMalik Y. Kahook is a professor of ophthalmology at the University of Colorado School of Medicine and co-founder of SpyGlass Pharma, which develops a sustained drug delivery platform for treating chronic ophthalmic diseases including glaucoma.
PMPatrick Mooney
Patrick MooneyCEO

Board

JM
Jake MerrillBoard directorPartner at Sands Capital Ventures
GPGeoff Pardo
Geoff PardoBoard director
BKBilal Khan
Bilal KhanBoard director
CY
Cynthia YeeinBoard Director2020–2025Partner at Vensana Capital
RZ
Roger ZhangBoard director
ABAli Behbahani
Ali BehbahaniinBoard directorPartner, Co-Head of Healthcare at New Enterprise Associates (NEA)
ZSZach Scheiner
Zach ScheinerinBoard of DirectorsPartner at RA Capital

Investors · 5

New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ali Behbahani · board
RA CapitalBoston
Samsara BioCapitalPalo Alto
Sands Capital VenturesreportedArlington · $10M – $30M
Vensana CapitalreportedMinneapolis

Reported raises · per SEC filings

Form D private placements

$134.8M disclosed across 4 rounds · 2019–2025

▶$75MraisedJun 2025 · 10 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jake MerrillDirector
  • Malik KahookExecutive Officer, Director
  • Geoff PardoDirector
  • Bilal KhanDirector
  • Cynthia YeeDirector
  • Roger ZhangDirector
  • Patrick MooneyExecutive Officer, Director
  • Ali BehbahaniDirector
  • Zach ScheinerDirector
Offering amount
$75M
Amount sold
$75M
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40MraisedJul 2023 · 7 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ali BehbahaniDirector
  • Patrick MooneyExecutive Officer, Director
  • Cynthia YeeDirector
  • Malik KahookExecutive Officer, Director
  • Roger ZhangDirector
  • Zach ScheinerDirector
Offering amount
$90M
Amount sold
$40M
First sale
Jul 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.7MraisedJan 2021 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Kirk NielsenDirector
  • Malik KahookExecutive Officer, Director
  • Ali BehbahaniDirector
  • Tak CheungDirector
  • Cynthia YeeDirector
  • Glenn SussmanExecutive Officer, Director
Offering amount
$37.5M
Amount sold
$13.7M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedJun 2019 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Malik KahookExecutive Officer, Director
  • Ali BehbahaniDirector
  • Glenn SussmanExecutive Officer, Director
Offering amount
$6M
Amount sold
$6M
First sale
May 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$510.6Mvaluation at IPOFeb 2026 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 2

by search overlap
Ois20 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.
Tenpoint Therapeutics12 shared keywordsTenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye. The company works with eye care professionals to advance therapies in the ophthalmology market.

Companies competing with Spyglass Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Spyglass Pharma do?
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.
Who founded Spyglass Pharma?
Spyglass Pharma was founded by Glenn Sussman, Malik Y. Kahook in 2019.
Who are Spyglass Pharma's investors?
Spyglass Pharma's investors include New Enterprise Associates (NEA), RA Capital, Samsara BioCapital, Sands Capital Ventures, Vensana Capital.
How much funding has Spyglass Pharma raised?
Spyglass Pharma has disclosed $134.8M raised across 4 rounds.
Where is Spyglass Pharma headquartered?
Spyglass Pharma is headquartered in Aliso Viejo, US.